Journal: Journal of medicinal chemistry

Article Title: Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Anti-Apoptotic Bcl-2 Proteins by Small-Molecules.

PMID/MRN: 27749061

Publication Date: 2016-Oct-17

Abstract:

A hallmark of cancer is the evasion of apoptosis, which is often associated with the upregulation of the anti-apoptotic members of the Bcl-2 family of proteins. The prosurvival function of the anti-apoptotic Bcl-2 proteins is manifested by capturing the pro-apoptotic Bcl-2 proteins through their BH3 death domains. Accordingly, strategies to antagonize the anti-apoptotic Bcl-2 proteins have largely focused on the development of low-molecular-weight, synthetic and selective BH3 mimetics ("magic bullets") to disrupt the protein-protein interactions between anti- and pro-apoptotic Bcl-2 proteins. In this way, apoptosis has been re-activated in malignant cells. Moreover, several such Bcl-2 inhibitors are presently being evaluated for a range of cancers in clinical trials, and show great promise as new additions to the cancer armamentarium. This review focuses on the major developments in the field of Bcl-2 inhibitors over the past decade, with particular emphasis on binding modes and the origins of selectivity for specific Bcl-2 family members.